



## **Mandate requesting ECHA opinions under Article 75(1)(g) of the BPR**

### **"Evaluation of the Endocrine disrupting properties of certain biocidal actives substances according to the new scientific criteria"**

#### **1. Background**

- (1) The scientific criteria for the determination of endocrine-disrupting properties ("the scientific ED criteria) pursuant to Regulation (EU) No 528/2012 of the European Parliament and Council ("the BPR") have been established under Commission Delegated Regulation (EU) 2017/2100 of 4 September 2017.
- (2) Pursuant to Article 2 of that Regulation, these criteria shall apply as of 7 June 2018, except for procedures where the Standing Committee on Biocidal Products has already voted on a draft Regulation approving (or not) an active substances.
- (3) During the 25<sup>th</sup> Biocidal Products Committee meeting of 25-26 April 2008, ECHA has adopted opinions on the approval of several active substances for use in biocidal products. For the active substances subject to these opinions, it has not been possible to get an opinion of the Standing Committee on Biocidal Products before 7 June 2018, in particular on a draft Implementing Regulation approving those substances.

#### **2. The question referred to ECHA**

- (4) Pursuant to Article 75(1)(g) of the BPR, ECHA is therefore requested to adopt revised opinions concerning the approval of the active substances listed in section 4 of the present mandate. The revised opinions must contain an assessment of the endocrine-disrupting properties of these active substances according to the new scientific ED criteria.

#### **3. Elements to be considered by ECHA when addressing this question**

- (5) For determining the ED properties of an active substance ECHA shall use any information already available in the application and consider whether additional information needs be requested from the applicant(s) in accordance with the principles agreed in document [CA-March18-Doc.7.3a-final- EDs- active substances under assessment.docx](#).
- (6) The earlier opinions shall be updated only for the part in relation to the assessment of the ED properties, unless the conclusion of this assessment affects the results of the risk assessment already performed or the

recommendations for approval. In the latter case, such assessment and recommendations shall also be updated.

#### **4. List of actives substances and opinions of ECHA concerned by the present mandate**

- (7) Revised opinions are requested on :
- (a) Active chlorine generated from sodium chloride by electrolysis:
1. Opinion on the application for approval of the active substance:  
Active chlorine generated from sodium chloride by electrolysis  
Product type: 1, ECHA/BPC/194/2018 adopted on 25 April 2018
  2. Opinion on the application for approval of the active substance:  
Active chlorine generated from sodium chloride by electrolysis  
Product type: 2, ECHA/BPC/195/2018 adopted on 25 April 2018
  3. Opinion on the application for approval of the active substance:  
Active chlorine generated from sodium chloride by electrolysis  
Product type: 3, ECHA/BPC/196/2018 adopted on 25 April 2018
  4. Opinion on the application for approval of the active substance:  
Active chlorine generated from sodium chloride by electrolysis  
Product type: 4, ECHA/BPC/197/2018 adopted on 25 April 2018
  5. Opinion on the application for approval of the active substance:  
Active chlorine generated from sodium chloride by electrolysis  
Product type: 5, ECHA/BPC/198/2018 adopted on 25 April 2018
- (b) Active chlorine released from hypochlorous acid:
1. Opinion on the application for approval of the active substance:  
Active chlorine released from hypochlorous acid Product type: 1,  
ECHA/BPC/199/2018 adopted on 25 April 2018
  2. Opinion on the application for approval of the active substance:  
Active chlorine released from hypochlorous acid Product type: 2  
ECHA/BPC/200/2018 adopted on 25 April 2018
  3. Opinion on the application for approval of the active substance:  
Active chlorine released from hypochlorous acid Product type: 3  
ECHA/BPC/201/2018 adopted on 25 April 2018
  4. Opinion on the application for approval of the active substance:  
Active chlorine released from hypochlorous acid Product type: 4  
ECHA/BPC/202/2018 adopted on 25 April 2018
  5. Opinion on the application for approval of the active substance:  
Active chlorine released from hypochlorous acid Product type: 5  
ECHA/BPC/203/2018 adopted on 25 April 2018
- (c) Carbendazim:

1. Opinion on the application for approval of the active substance: Carbendazim Product type: 7, ECHA/BPC/204/2018 adopted on 25 April 2018
2. Opinion on the application for approval of the active substance: Carbendazim Product type: 10, ECHA/BPC/205/2018 adopted on 25 April 2018

#### **5. Deadline for the ECHA opinions**

- (8) ECHA shall adopt the revised opinions as soon as possible. ECHA shall inform DG SANTE no later than 6 months after receiving this mandate of the date by which the opinions on each substance can be finalised or, at least, on the next steps in the process planned for each substance to deliver these opinions (e.g.: consultation of BPC Working Groups and/or the Endocrine Disrupter Expert Group, and the related timing).